Bromerguride

This classification denotes a dopamine antagonist with the molecular formula C20H25BrN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HX58M2377W, chemically known as 3-(2-bromo-9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but generally known as bromerguride, which bears US NIH Compound Identifier 71266. European Medicines Agency schedules Bromerguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05911MIG. The term BROMERGURIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BROMERGURIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromerguride under HS 29396900 and SITC 54146. As of Q4 2014, BROMERGURIDE remains the US FDA Preferred Term for this commodity. Bromerguride bears US NLM identifiers UMLS ID C0054092 and NCI Concept Code C73311. SMILES: BRC1[NH]C2C3C1CC1N(CC(NC(=O)N(CC)CC)C=C1C3CCC2)C.